유럽 ​​오메가-3 성분 의약품 시장 – 2030년까지의 산업 동향 및 예측

유럽 ​​오메가-3 성분 제약 시장 분석 및 규모

노령 인구는 콜레스테롤을 낮추고 심장 건강을 개선하는 제품에 대한 기회를 만들어낼 것으로 예상되며, 특히 유럽에서 그렇습니다. 현재, 여러 제조업체가 의약품을 위한 새롭고 혁신적인 오메가-3 성분을 개발할 수 있는 경쟁 우위를 만들어낼 것으로 예상되는 수많은 연구가 진행 중입니다. 결과적으로 유럽에서 라이프스타일과 연령 관련 질병이 증가함에 따라 보충제 및 기능성 식품 부문의 성장이 개선되고 있으며 매출 점유율은 52%입니다.

 Data Bridge Market Research는 2023-2030년 예측 기간 동안 제약용 오메가-3 성분 시장의 성장률을 분석합니다. 제약용 오메가-3 성분 시장의 예상 CAGR은 언급된 예측 기간 동안 약 10.5%인 경향이 있습니다. 시장은 2022년에 1억 5,812만 달러로 평가되었으며, 2030년까지 3억 5,147만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

유럽 ​​오메가-3 성분 제약 시장 범위 및 세분화

Market Definition

Omega 3 ingredients are naturally occurring polyunsaturated fatty acids and nutrients that are essential for optimal human health. There are three kinds of omega 3 ingredients, namely, eicosapentaenoic acid (EPA), alpha-linoleic acid (ALA), and docosahexaenoic acid (DHA). EPA and DHA are mostly extracted from fish and ALA is mainly extracted from plants sources such as seeds and nuts.

Europe Omega-3 Ingredients for Pharmaceuticals Market Dynamics

Drivers

• Increasing Demand of Docosahexaenoic acid (DHA)

Docosahexaenoic acid (DHA) type is in higher demand due to the increasing utilization of the product in infant formulas for the betterment of the overall health of an infant. In the human diet, DHA is the most vital and abundant omega-3 fatty acid, which helps in maintaining the overall health of the human body. DHA is a main component for the development and maturity of an infant's brain and eyesight. Furthermore, it is extensively used in nutritional supplements and fortified foods. It is also widely used in treating dementia, coronary artery disease (CAD), attention deficit hyperactivity disorder, and Type 2 diabetes. DHA helped in increasing f longevity have also resulted in its use in elderly nutrition products. Thus, this factor increases the growth of the market.

• Rising Consumption of Omega-3 Supplements Among Adult Consumers

Omega-3 fatty acids, mainly EPA and DHA, are required in the human diet for proper growth, development, and good health. These have been found to be very beneficial for heart health, joint and inflammation support, cognitive function, eye health, pregnancy and healthy child development, and immune function, among other benefits. Also, algae omega-3 ingredients used in dietary supplements, with the primary focus of EPA-only products, will be the future focus of the market in the region. Also, consumers are looking for several new developments in omega-3 products and their focus on particular health benefits. The benefits of omega-3s in protecting adult eyes from age-related macular degeneration and dry eye syndrome are also influencing the market growth. This factor improves the market growth.

Opportunities

• Huge growth in concentrated forms of algal omega-3 ingredients

New ultra-high concentrated omega-3 ingredients offer several benefits to consumers willing to pay a higher premium price for high-end products. Several suppliers are investing in the production of high concentrated algal omega-3 products, estimating increased demand to drive the sales. The market for concentrates has also been increasing, as more consumers become aware of the benefits of algal omega-3 and seek the benefits of higher doses. Several major companies are involved in omega-3 manufacturing that has started to strategically capitalize the existing business expansion opportunity.

• Increasing Research Activities

Numerous research studies have developed a link between consumption of fatty fish and lowering of coronary heart diseases. For instance, fish oils are widely used as a supplement to balance the required dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Furthermore, several local players, such as Pharma Nord, have launched mega-3 dietary supplements targeting varied sets of population. For instance, the company’s pure and natural fish oil in capsules which are widely available in a natural lemon flavor, is targeted toward children to increase their health benefits, thus leading to its increased purchases by parents. Thus, this factor helps to create much opportunities for the growth of the market.

Restraints/Challenges

• Side Effects of omega-3 ingredients

There are various side-effects associated with the omega-3 ingredients for pharmaceuticals. Effects such as burping, diarrhea, heartburn, joint pain, stomach pain or discomfort, vomiting, constipation, nausea. Thus, these adverse effects affect the growth rate by decreasing the adoption of omega-3. This impedes the market growth.

• Increasing Negative Consumer Perception About omega-3 ingredients

Negative consumer perception associated with the smell and taste of omega-3 ingredients is also anticipated to limit the growth of the market. These unstable fatty acids can damage through enzymatic or chemical oxidation to form compounds that give foods a fishy smell. Additionally, fresh fish oil has no fishy taste or smell, just like fresh fish. People feel hesitant to adopt for omega-3 ingredients. Thus, this hampers the market growth.

This omega-3 ingredients for pharmaceuticals market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the omega-3 ingredients for pharmaceuticals market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2021, Omega-3 related supplier GC Rieber VivoMega announced its plans to enhance production facilities and storage tanks to accommodate more ingredients in the upcoming years.
• In 2021, KD Pharma Group introduced Alga3, a sustainable, vegan omega-3 solution. KD Nutra's superior technology and production flexibility enable for a huge range of omega-3 concentrates. The company can personalize the EPA and DHA ratio on customer needs, and for any kd-pür fish oil, there is a matching Alga3 plant-based solution.
• In 2021, AlgaeCytes Limited announced plans to build its first commercial plant in Dessau, Saxon-Anhalt, Germany. The plant will be owned and operated by the Company’s German subsidiary, AlgaeCytes Germany GmbH.

Europe Omega-3 Ingredients for Pharmaceuticals Market Scope

The Omega-3 ingredients for pharmaceuticals market is segmented on the basis of source, type, forms, therapeutic areas, population type, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

• Marine
• Plant

Type

• Docosahexaenoic Acid (DHA)
• Eicosapentaenoic Acid (EPA)
• Alpha-Linolenic Acid (ALA)

Forms

• Liquid
• Dry

Therapeutic Areas

• Cardiovascular Diseases
• Autoimmune Diseases
• Bone & Joint Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Skin Health
• Cancer
• Others

Population Type

• Adults
• Children

Distribution Channel

• Direct
• Indirect

Omega-3 Ingredients for Pharmaceuticals Market Regional Analysis/Insights

The Omega-3 ingredients for pharmaceuticals market is analyzed and market size insights and trends are provided by source, type, forms, therapeutic areas, population type, and distribution channel as referenced above.

The major countries covered in the Omega-3 ingredients for pharmaceuticals market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

독일은 조류 기반 EPA 성분과 강화 제품의 증가로 인해 예측 기간 내내 제약 시장을 위한 오메가-3 성분의 긍정적인 성장을 목격했습니다. 영국 정부는 성인의 일반 식단에서 EPA와 DHA의 권장량을 200mg에서 450mg으로 늘렸습니다. 영국의 소비 패턴은 다릅니다. 27%만이 기름진 생선을 섭취하고, 성인과 어린이의 대부분은 보충 식품에서 다른 EPA와 DHA 공급원에 의존합니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 유럽 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 유럽 오메가-3 성분 제약 시장 점유율 분석

제약 시장을 위한 오메가-3 성분 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 유럽 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 제약 시장을 위한 오메가-3 성분과 관련된 회사의 초점에만 관련이 있습니다.

제약품용 오메가-3 성분 시장에서 활동하는 주요 기업은 다음과 같습니다.

• Avestia Pharma(인도)
• 노바셉(프랑스)
• AbbVie Inc.(미국)
• KD Pharma Group(일본)
• BASF SE(독일)
• 코르비온(네덜란드)
• DSM(네덜란드)
• 아스트라제네카(영국)
• GSK plc. (영국)
• Fresenius Kabi AG(독일)
• 크로다 인터내셔널 주식회사(미국)
• AMARIN CORPORATION (아일랜드)
• ANI Pharmaceuticals, Inc. (미국)
• 에팍스(노르웨이)
• Strides Pharma Science Limited(인도)
• Pharma Marine AS(노르웨이)
• KinOmega Biopharm Inc. (중국)
• 캠버 파마슈티컬스(Camber Pharmaceuticals, Inc.) (미국)

SKU-55584